Request Demo

Last update 08 May 2025

Colitis, Lymphocytic

Last update 08 May 2025

Basic Info

Synonyms

Colitis, Lymphocytic, Lymphocytic Colitis, Lymphocytic colitis

+ [12]

Introduction

A subtype of MICROSCOPIC COLITIS, characterized by chronic watery DIARRHEA of unknown origin, a normal COLONOSCOPY but abnormal histopathology on BIOPSY. Microscopic examination of biopsy samples taken from the COLON show infiltration of LYMPHOCYTES in the superficial EPITHELIUM and the underlying connective tissue (lamina propria).

Drugs associated with Colitis, Lymphocytic

Mesalamine

Target

PP2A

Mechanism

PP2A inhibitors

Active Org.

AbbVie, Inc. [+12]

Originator Org.

Sanofi

Active Indication

Ulcerative colitis, active moderate [+7]

Inactive Indication

Colitis, Collagenous [+9]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Switzerland

First Approval Date01 Jan 1984

Budesonide

Target

Mechanism

GR agonists

Active Org.

Calliditas Therapeutics AB [+31]

Originator Org.

AstraZeneca Pharmaceuticals Co. Ltd.

Active Indication

Glomerulonephritis, IGA [+9]

Inactive Indication

Acute Graft Versus Host Disease [+21]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date01 Oct 1981

Clinical Trials associated with Colitis, Lymphocytic

NCT05579444

/ TerminatedNot Applicable

Systems Biology of Gastrointestinal and Related Diseases

This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and remissions, or progression of their disease.

Start Date11 Nov 2022

Sponsor / Collaborator

Viome Life Sciences, Inc.

NL-OMON45110

/ CompletedNot ApplicableIIT

Risk Factors for Microscopic Colitis. A Dutch Case-Control Study - Risk factors for MC

Start Date03 Jul 2014

Sponsor / Collaborator-

NCT01928667

/ CompletedNot ApplicableIIT

Risk Factors for Microscopic Colitis: A Dutch Case-Control Study

The purpose of the study is to assess among others environmental and hygiene-related risk factors for microscopic colitis (MC), a common diarrheal disease.

Start Date01 Jul 2014

Sponsor / Collaborator

Maastricht UMC+

100 Clinical Results associated with Colitis, Lymphocytic

100 Translational Medicine associated with Colitis, Lymphocytic

0 Patents (Medical) associated with Colitis, Lymphocytic

670

Literatures (Medical) associated with Colitis, Lymphocytic

01 Mar 2025·Clinical Gastroenterology and Hepatology

Cholecystectomy is a Risk Factor for Microscopic Colitis: A Nationwide Population-based Matched Case Control Study

Article

Author: Lindkvist, Björn ; Sun, Jiangwei ; Peery, Anne ; Ludvigsson, Jonas F ; Bergman, David ; Ebrahim, Fahim ; Maret-Ouda, John

BACKGROUND & AIMSStudies have linked bile acid malabsorption and microscopic colitis (MC), with some patients with MC responding to treatment with bile acid sequestrants. However, the literature on cholecystectomy as a risk factor for MC is inconclusive. Therefore, we investigated the relationship between cholecystectomy and MC on a nationwide scale to provide more definitive insights.METHODSWe conducted a nationwide matched case-control study involving 13,554 patients diagnosed with MC between 1981 and 2017 in Sweden who were matched to 64,886 controls. Data on MC were obtained from Swedish pathology registers, and controls were randomly selected from the general population and matched according to birth year, sex, county of residence, and calendar year. Moreover, MC-free full siblings to patients with MC were identified. Information on cholecystectomy was collected from the Swedish National Patient Register. Adjusted odds ratios (aORs) were calculated using multivariable-adjusted conditional logistic regression.RESULTSThe median age at diagnosis was 63.5 years (interquartile range [IQR], 51.0-73.4 years), and 72.3% of MC patients were women. Among patients with MC, 342 (2.5%) had undergone a cholecystectomy before diagnosis, compared with 687 (1.1%) in the control group. This yielded an aOR of 2.36 (95% confidence interval [CI], 2.07-2.69) for earlier cholecystectomy in patients with MC. The corresponding aORs for collagenous colitis and lymphocytic colitis were 1.87 (95% CI, 1.48-2.36) and 2.65 (95% CI, 2.26-3.12), respectively. When compared with siblings, the aOR was 1.49 (95% CI, 1.21-1.85).CONCLUSIONSCholecystectomy is associated with an increased risk of subsequent MC. These findings have implications for surgeons and general practitioners and underscore the need for further research into the underlying association between bile acid and MC.

31 Dec 2024·Annals of Medicine

Factors associated with long-term clinical outcome in microscopic colitis

Article

Author: Sakuraba, Atsushi ; Micic, Dejan ; Komaki, Yuga ; Keyashian, Kian ; Miyatani, Yusuke ; Komaki, Fukiko

BACKGROUND AND AIMSMicroscopic colitis has been increasingly recognized as a cause of chronic diarrhoea. We aimed to characterize the role of disease-related factors and treatments on the clinical outcomes of microscopic colitis.METHODSWe retrospectively reviewed the medical records of patients with microscopic colitis who were treated at the University of Chicago and Oregon Health & Science University between August 2010 and May 2016. Patient characteristics and treatments were evaluated as predictors of clinical outcomes using univariate and multivariate analyses. Clinical remission was defined as no symptoms associated with microscopic colitis based on physician assessment and histologic remission was defined as no evidence of histological inflammation of microscopic colitis.RESULTSSeventy-two patients with microscopic colitis were included in the study (28 with lymphocytic colitis and 44 with collagenous colitis). Non-steroidal anti-inflammatory drugs, proton pump inhibitors and selective serotonin reuptake inhibitors were used in 23 (31.9%), 14 (19.4%) and 15 (20.8%), respectively, at the time of diagnosis. Among 46 patients with adequate follow-up data, 25 (54.3%) patients achieved clinical remission. Response to budesonide (p = .0002) and achieving histologic remission (p = .0008) were associated with clinical remission on univariate analysis. On multivariate analysis, budesonide response (p = .0052) was associated with clinical remission (odds ratio 25.00, 95% confidence interval 2.63-238.10). Among 22 patients who underwent a follow-up colonoscopy, five patients (22.7%) achieved histologic remission. All patients with histologic remission maintained clinical remission without medication, whereas only two patients (11.8%) were able to discontinue medical therapy when histologic inflammation was present (p = .0002).CONCLUSIONSIn the present cohort of patients with microscopic colitis, a favourable response to budesonide was significantly associated with long-term clinical remission, and all patients achieving histological remission were able to maintain clinical remission without further medical therapy. Larger studies are required to confirm these findings.

01 Aug 2024·Heliyon

SARS-CoV-2 as a potential trigger for microscopic colitis in a young adult: A case report

Article

Author: Kamaleddine, I. ; Prall, F. ; Schafmayer, C. ; Alwali, A.

This case highlights the potential role of SARS-CoV-2 in triggering lymphocytic colitis, emphasizing the need for further research and vigilance in identifying potential post-COVID-19 GI complications. We describe a case of a young adult who experienced chronic diarrhea and abdominal pain for 10 months after a SARS-CoV-2 infection. Extensive laboratory and imaging investigations yielded no significant findings. Despite a preliminary diagnosis of irritable bowel syndrome and symptomatic treatment, symptoms persisted. Colonoscopy with biopsies revealed unremarkable colonic mucosa but confirmed moderate lymphocytic infiltration consistent with lymphocytic colitis. Treatment with budesonide achieved complete symptom resolution. The findings underscore the importance for clinicians to consider triggered microscopic colitis in patients presenting with persistent diarrhea following SARS-CoV-2 infection.

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis